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Abstract

The isolated rat diaphragm was used as an in vitro model to
quantitate the effects of insulin on glucose uptake.
Experi¬
ments were conducted on quarter diaphragms to test the effects
of in vitro treatments.
Using this technique, it was found
that insulin significantly affected glucose uptake when added
in vitro at a concentration of 100 uU/ml.
The addition of
-estradiol (2 x 10-3 uM) had no effect on either basal
or insulin-stimulated uptake.
Furthermore, perincubation of
diaphragm muscle in estradiol (2 uM) followed by incubation
with estradiol (2 x 10~3 uM) and insulin had no effect on
glucose uptake.
In a second set of experiments, animals were injected in vivo
with sesame oil (Group I) and estradiol in sesame oil (Group II)
for two weeks.
The excised hemidiaphragms were then incubated
with and without added insulin in vitro.
In the basal state,
estrogen pretreatment was found to reduce glucose uptake by
16% as compared to control (p<.001).
In the presence of
insulin, pretreatment was associated with a 22% increase in
glucose uptake when compared to Group I (p<.001).
Insulin
increased the mean glucose uptake above the basal state by 38%
in control animals and 103% in treated animals.
This represents
a 2 to 3 fold rise in sulin responsiveness after estrogen
administration.
Estradiol treatment was not associated with
changes in fasting plasma immunoreactive insulin or glucose
concentrations.
These findings support previous data that show estrogens to
have a protective effect on the development of diabetes in
subtotally pancreatectomized animals.
Our experiments suggest
that the mechanism for this improvement in carbohydrate
tolerance may be the increased insulin sensitivity of muscle
following estrogen treatment.
Oral contraceptive-induced
glucose intolerance may be related to the use of synthetic
agents in combination, especially mestranol with some progestin
compounds, and may be mediated by an increase in growth hormone
concentrations.
Estradiol has been shown to increase the glycogen content of
certain tissues independent of insulin action.
In the rat
diaphragm, increased insulin sensitivity alone can augment
glycogen synthesis when animals are treated in vivo.
When
incubated in a medium containing glucose but no insulin, the
treated muscle is expected to take up less glucose to supply
substrate for glycogen synthesis.
Our failure to demonstrate
an effect with in vitro administration of estradiol may be
due to the relative insensitivity of skeletal muscle to the
sex steroids.
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Introduction
The first attempts at understanding the interaction of
sex steroids and carbohydrate metabolism showed that crude
estrogenic preparations
animals

(6).

Subsequent reports were contradictory,

showing exacerbation,
diabetes

improved glycosuria in diabetic

(42,128).

and some,

some

amelioration of experimental

Amidst the controversy,

it was recognized

that the effects on carbohydrate metabolism varied from
animal

to animal,

steroid to steroid and at varying doses.

More recent biochemical studies have examined the problem
at a cellular level

in a non-carbohydrate-intolerant animal

model.
The advent of oral contraceptives two decades
duced a nex-/ factor.

Large numbers

mated to be greater than

of women

ago intro¬

(currently esti¬

20 million world-xvide

(194))

were

taking agents whose metabolic side effects were not completely
understood.

The first reports suggesting such effects

carbohydrate tolerance appeared promptly;
et

al.

(103)

in

1963,

on

Waine

briefly reported on several patients who showed

deterioration in their glucose tolerance on horethynodrel plus
mestranol

(Enovid).

Since then,

attempted to confirm or deny this

numerous studies have
observation.

The present investigation was carried out to study a
narrow portion of the overall problem:

namely,

does estrogen,

specifically the naturally-occurring 17/3-estradiol,

affect the

insulin-mediated transport of glucose into muscle cells?

The

results of this work will be presented in

the context

existing data in animals and human subjects.

of the

Since the vast

bulk of insulin-sensitive glucose utilization in physiologic
states is by muscle and fat,
for insulin action

the former was chosen as

a model

Materials and Methods

The method used was the rat diaphragm assay first
described by Gemmill

technique consists

(63)

and modified by others

of using the excised muscular portion of

the rat diaphragm in vitro,

(The method had been used exten¬

sively in measuring insulin-like
radioimmunoassay,)

(19,23,27-28,

The muscle,

activity before the advent of
when incubated in glucose-

containing buffer solution with and without added insulin,
takes up glucose from the medium.
the medium,

Glucose disappearance from

glycogen formation in the diaphragm or C
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-glucose

incorporation into muscle have been used as markers of insulin
action on carbohydrate metabolism.
Animals
Non-pregnant,
(Camm Research,

adult,

Wayne,

female rats

N.J.)

of the Wistar strain

were used in all the experiments

except for a small group of males studied for comparative
purposes.

All

animals were kept in separate cages at least

10 days prior to the experiment.
food ad libitum^

They were allowed water and

the diet consisting of Purina Laboratory Chow

with the following composition:
Protein
Fat
Fiber
TDN
NFE (difference)
Kcal/Gm

23.2%
4.5
3.8
77.0
52.5
4.16
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The animals were kept in a constant room temperature of
with lighting from 6:00 a.m.

until

75-8Q°F

6:00 p.m.

Most animals did quite well under these conditions.
obtained from the supplier,
100 Gm.

these rats weighed approximately

Weight gain ranged from 15-25 Gm.

nearly 200 animals so treated,
sacrificed

When

per week.

Of the

only three died before being

(none had been injected).

Rats weighed 120-I80g

at the time of study.
Buffer Solution:
Incubations were carried out in Krebs-Ringer bicarbonate
buffer

(105).

As described by Umbreit et

al.

(195),

solutions

of the various components of the buffer were made up to con¬
centrations five times normal

to improve stability.

was prepared weekly from these stock solutions;
vitro concentrations

the final

in

are given below:

(Reagent-grade chemicals
NaCl

KC1
CaCl
KH2PO4
MgS04.7H20
NaHC03

in distilled I^O)
0.154
0.154
0.110
0.154
0.154
0.154

M
M
M
M
M
M

The solution was gassed for 10 minutes with
yield a final pH of

Buffer

7.4.

95% 02/5% C02 to

(3 -D-glycose was weighed and added

to the buffer for a final concentration of 150 mg/100 ml.
Solutions were stored in glass-stoppered bottles in a refrig¬
erator
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Early work using the rat diaphragm was carried out in
buffer media with added insulin.
as well

However,

it has been shown

in this system

(34)

as others that up to 80% of

insulin can be

lost by adhesion to glassware.

Bovine Serum Albumin

(Sigma Chemical Co.,

used to prevent this

loss of insulin activity.

Hence,

1%

Lot #33C-8160)

was

Chemicals
The insulin used was regular crystalline zinc insulin
(Eli Lilly)

obtained from the hospital pharmacy.

U80 insulin

(Lot #2L13854)

Improved biological

Initially,

was used with poor results.

activity

(i.e.,

increased glucose uptake)

was found using U100 regular insulin

(Lot #6PW79C)

and it is

the latter which was used in all the experiments reported
here.
Insulin was prepared weekly by dilution of the vial
contents in veronal buffer
0.02 M,
final

pH=8.6)

(barbital/Na diethylbarbiturate,

containing 2% Bovine Serum xAlbumin.

insulin concentration was 0.1 U/ml;

thus,

The

10 microliter

aliquots added to 10 ml of Krebs-Ringer buffer yielded a final
insulin concentration in the medium of 100 microunits/ml.
17/3-estradiol

(estra-'*'' ^^

-triene-3,17 -diol)

grade,

chromatographically pure steroid

Corp.,

Lot #201120)

was A

(California Biochemical

provided as the solid and refrigerated.

For in vitro use:

Peak plasma concentrations of estradiol

in adult femal Wistar rats were shown by Brown-Grant et al.

to

*
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be

30 pg/ml

(22).

Estradiol was weighed on a Sartorius

Automatic Pre-weighing Balance
ethanol

to a concentration of

(d<0.1mg)
1.0 mg/ml.

and dissolved in
Serial dilution

in distilled water yielded final solutions of 0.5,
0.05 ug/ml.

0.1,

and

One micro-liter aliquots of these solutions

1.0 ml incubation medium gave final concentrations
mating 500,

100,

.

and 50 pg/ml.

in

approxi¬

Solutions of estradiol were

prepared weekly and stored under refrigeration.
For in vivo use;

In attempting to arrive at a dose of

estradiol which would approach the pharmacologic level
estrogen in oral contraceptives,

of

it became evident that no

firmly established amounts were recommended in rats.
basis of the evidence quoted below*

On the

10 ug/100 Gm body weight

17/^-estradiol injected subcutaneously in sesame oil was chosen.

*The most commonly-used estrogen derivatives in the oral con¬
traceptives are ethinyl estradiol and its 3-methyl ether,
mestranol.
Saunders (154) and Kind et al. (99) state that
ethinyl estradiol and 17/3-estradiol have comparable estrogenic
activity whereas Desaulles et al. (39), using vaginal epithelial
cornification and inhibition of ovulation in the rat, believe
that ethinyl estradiol possesses only l/10th the "estrogenic"
activity of 17^-estradiol.
Kind reports that mestranol possesses
only l/5th the activity of the more potent estrogens.
Using these
rough criteria, one arrives at doses ranging from 0.02 to 0.2
ug/100 Gm body weight of estradiol in women weighing 60-65 Kg.
Studies in the rat yield somewhat different results.
Basabe et
al. (8) used 4 ug per day of estradiol in their rats weighing
100 Gm. and above.
Kind showed that a dose of 0.03 ug of 17/#estradiol produced a significant pituitary effect and that 0.2
ug total dose is needed for maximum inhibition of gonadotrophin
secretion but does not report weights of the rats.
Desaulles
found that 3.0 to 10.0ug/100 Gm/day of 17^-estradiol injected
subcutaneously in intact rats is sufficient to prevent ovulation.
This is comparable to the smallest dose of estrone (1.0 ug/100 Gm)
found by Saunders (151) to prevent conception, estradiol being 10
times more potent than estrone as a uterotropic agent but only 2
to 4 times as potent as a gonadotrophin inhibitor in spayed rats.
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Solid estradiol was weighed and dissolved in a small
of ethanol.

amount

The ethanol was removed by evaporation and

reagent grade sesame oil was added to a concentration of 15

3
ug/0.1 ml estrogen.

H-estradiol

of known activity was dis¬

solved in a similar concentration and activity measured one
week and one month later with no detectable separation of the
estrogen.

The solution was

stable at room temperature.

Animals were not anesthetized for injection;
used to inject daily volumes up to 0.12 ml
the

#25 needles were

subcutaneously in

loose lower abdominal skin.

Assays
Insulin was measured by radioimmunoassay in Dr.
laboratory.

The technique is described elsewhere

Felig's

(149).

Glucose determinations were carried out by the glucose
oxidase method

(85)

using the Glucostat^ reagent kit

(Worthington Biochemical Corporation,
method depends

N.J.).

The

on the following sequence of reactions:

Glucose + 02

->

H2°2 + Reduced Chromogen
Vials of the enzyme,
dianisidine,

Freehold,

->

H2^2

+ Glucon:*-c Acid

Oxidized Chromogen + H20

glucose oxidase,

and the chromogen,

are diluted with distilled water,

blood filtrate added,

o-

a 1:20 Somogyi

and incubation carried out at room

temperature for ten minutes.
fied for these experiments

This procedure had to be modi¬

(150,205).

a

Deproteinization:

0.3 ml

of the sample is pipetted

into 4.5 ml distilled water using a Becton-Dickinson Biopette
Automatic Pipetter.
by,

0.9 ml

of 0.34 N NaOH is added followed

1.0 ml of CDSC>4 solution

precipitate.

(0.25% W/v),

yielding a gelatinous

Following centrifugation at 3000 RPM for 15

minutes at 3°C.,

0.4 ml aliquots

of supernatant could be used

for glucose determination without interference from added
albumin.
Glucose determination:

Instead of making up Glucostat

reagent to the 60 ml total volume recommended by the manufac¬
turer,

a more dilute solution

proved more useful.

6.0 ml

(100 ml) was made up since it

of the dilute reagent was added

to the deproteinized sample and incubated for 30 minutes at
37°C.

At the end of the precisely-timed incubation period,

samples were removed from the bath,
with the addition of 2 drops

the reaction stopped

4.0 N HC1,

and the tube allowed

to stand at room temperature for ten minutes.
Tubes were read in a Coleman Junior II Spectrophoto¬
meter at 425 nm,

calibrated against blank and 50,

150 mg% glucose standards.

100 and

The standard curve was linear

throughout the range studied and error was less than - 5 mg%.
Description of the Rat Diaphragm Technique:
All animals were fasted for 24 hours prior to the morning
of the experiment but allowed water ad libitum.
diurnal variations,
and 11:00 a.m.

To minimize

animals were sacrificed between 9:00 a.m.

Three to four animals were used each day.

those animals receiving injections of estrogen,

no dose of

In
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estradiol was given on the morning of the sacrifice of the
rat.
Animals were decapitated using a guillotine
Apparatus)

and allowed to exsanguinate.

(Harvard

Within one minute,

the abdomen was quickly opened in a V-shaped incision carried
from the suprapubic area to the lateral rib cage bilaterally.
This procedure effectively exposes the xiphoid process which
r
was then grasped with a hemostat and lifted superiorly and
caudally,

exposing the abdominal aspect of the diaphragm.

this point,
present.
phragm,

At

peristalsis and cardiac fibrillation was still

A nick was made in the central portion of the dia¬
the resulting loss of the negative intrapleural

pressure causing the diaphragm to billow out into the abdomen.
Using 1/4 inch straight scissors,
at its xiphoid insertion.

the diaphragm was incised

The incision was then carried

around both borders interiorly,

staying as close

ho the

thoracic wall as possible and attempting not to cut a ragged
or scalloped edge.
attachment,

When freed from its circumferential

the thoracic aspect of the diaphragm was care¬

fully exposed,

adherent pleura removed,

and a hemostat

placed on the inferior vena cava on both sides of the dia¬
phragm.
first,

The IVC was then transected in its thoracic portion
between hemostat and diaphragm.

The aorta could be

divided with no bleeding and the adherent lungs bluntly
dissected away.

Returning to the abdominal surface of the
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diaphragm,

the inferior vena cava and the tightly-adherent

hepatic ligaments were divided.

In practice,

this

latter

portion of the dissection is invariably bloody and any
attempt to prevent injury to the

liver would have so pro¬

longed the removal of the diaphragm that the best course was
to keep the muscle as far as possible from the pool of blood
that gathers promptly upon separation from the liver and to
quickly sever the remaining connections to the posterior
thoracic wall.
The excised,

\tfhole diaphragm was placed in 5 ml iced

Krebs-Ringer buffer in a glass petri dish

(saturated with

°2//C02 but contain*n9 no glucose or insulin).

The central

tendinous and membranous portion was separated from the more
peripherally-located muscle,
removed,

the cut edge trimmed,

fat

and blood in larger vessels gently expressed out.

The final specimen had a horseshoe shape as in Figure IB.
Depending on the experiment,

one or three cuts were made to

yeild hemi- and quarter-diaphragms,

Fig.

1

respectively.

Appearance of excised rat diaphragm immediately after
removal from animal (A) and prior to incubation (B).
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Incubation:
Slices of muscle were transferred to a clean beaker
containing 10 ml of buffer with glucose (150 mg%) but no
albumin or insulin,

and the solution gently bubbled with a

gas mixture of 95% 02/5% CO, for 15 minutes at room tempera¬
ture.

This preincubation period served several purposes:
1.
2.
3.

4.
5.

Saturation of tissues with oxygen.
Washing blood, tissue fluid and endogenous
insulin from muscle.
Allowing smoother equilibration of tissue
from its Ooc. wash medium to the 37° incubation
medium.
Removal of endogenous insulin activity as a
factor by approaching half-life in vitro.
The presence of a high physiological concentration
of glucose in the pre-incubation stage would pre¬
sumably provide a more reliable baseline for the
subsequent incubation since mass action movement
of glucose into cells would be minimized.

At the end of the preincubation period,

the tissue was

removed from the buffer, gently blotted on filter paper,

and

placed in a 10 cc Erlenmeyer flask containing 1.0 ml of buffer
with glucose (150 mg%),
insulin (100 uU/ml).

albumin (1%),

and without or with

After making certain that all the tissue

in the flask was immersed in the medium, the neck was sealed
with a rubber bung.

Two #19 needles were inserted through

the bung and used to fill the flask with 95% Q?/5% CO^

).

2

fia s

Figure 2

(Figure
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The flasks were incubated at 37°C. in a Dubnoff
Metabolic shaking incubator at 100 oscillations per minute.
After three minutes,

the needles were removed from the rubber

bungs and the flasks remained sealed for the duration of
incubation,

57 minutes.

At the end of this period,

flasks were removed from the bath,
further reaction in the muscle,

the

placed in ice to stop

and the tissue carefully

removed with a fine-toothed forceps.

Each piece of muscle

was weighed on a Mettler P163 Balance (d=l mg) after being
blotted on filter paper.

Tissue weight is thus the wet

weight.
Calculations:
Glucose concentration at the start of incubation was
measured from the stock solution prepared for each day’s
experiments.

Final glucose concentration in each flask was

determined in duplicate samples as described above.
the change in glucose concentration per 100 ml
50 mg%),

(e.g.,

Knowing
A =

the uptake of glucose per 1.0 ml of medium by the

muscle strip is easily obtained (0.5 mg).

This value is

divided by the wet weight of the tissue in the flask in
grams and the glucose uptake finally expressed as milligrams
glucose taken up per gram wet weight of muscle per hour
(mg/g/hr).
Experiments:
1.

In vitro:

For these experiments,

the diaphragm of

each animal was divided into quarters, yielding one control
and three portions undergoing treatment.

The following groups
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of experiments were performed:

1.
2.
3.
4.

Control (with and without insulin)
Estradiol in vitro with and without insulin

Pre-incubation with estradiol followed by
incubation with estradiol
Incubation with ethanol (control for estradiol
diluent)

When "pre-incubated",

the tissue was exposed to various con¬

centrations of estradiol in the preincubation stage before
transfer to the incubation medium where the same concentration
of estradiol was present.

In all these studies,

each animal

served as its own control.
2.

In vivo:

In these experiments animals pretreated

with estrogen for 2 weeks were compared to vehicle-treated
controls.

The diaphragms were divided into 2 equal halves

and incubated as described above but with only insulin added.
Obviously,

total glucose uptake in this latter technique was

higher than with smaller amounts of tissue per flask (i.e.,
quarter-diaphragms) with less variability in the assay.
Group I,
Group II,

controls.
estrogen pretreated.

A subgroup of Groups I and II animals was used to deter¬
mine fasting blood sugars and immunoreactive insulin
levels.

(IRI)

Since it was not practical to collect blood samples

after decapitation

(tissue factors increasing coagulability,

relatively small volumes obtainable,
of the diaphragms),
ether anesthesia.

need for quick removal

vena caval puncture was performed under
Samples were collected in heparinized
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tubes, centrifuged at 5,000 RPM at 3°C. for ten minutes,
and plasma stored at -5°C. for insulin and glucose determin¬
ations .

Statistical Analysis:
Due to the number of groups being compared with resultant
large numbers of comparisons,
was not appropriate.

Hence,

a simple t-test for significance
all experiments were initially

analyzed according to a repeated measures analysis of variance
design.
follows

Specifically,

the analyses were considered to be as

(* indicates the repeated measure factor):

In vivo experiments (pretreatment with estradiol):
Subjects (rats) nested in pretreatment (with or
without estrogen) crossed with treatments (with
or without insulin in vitro).*
In vitro experiments:
1.
2.
3.
4.

Control
Estradiol
Ethanol
Preincubation with
estradiol

Subjects X treatment
where each subject
acted as its control,

Where an omnibus F-test in the analysis of variance proved to
be significant, differences between the means of individual
groups were tested for significance using the Newman-Keuls
procedure for evaluating q,

the studentized range statistic

where
q = X2 - X!
o—#

(S.e.)-
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The Neuman-Keuls procedure corrects significance estimates
for the effect of multiple comparisons in relation to the
actual degrees of freedom.

These adjusted probabilities are

a fairer and more conservative estimate of the significance
of difference between means than a simple t-test.

XO

Results
1,

In vitro treatment of quarter-diaphragms.

A.

Variation of total weight of diaphragm

Since it seemed likely that some of the rat-to-rat
variation in insulin responsiveness of the tissue was due
to different weights of animals

(cf. Liebecq,

113), rat

weight at the time of sacrifice was examined in relation to
the total wet weight of the diaphragm after incubation.
There was a significant relationship that was linear in
nature in the weight range of the rats used in these exper¬
(Figure 3).

"Toioi

We»'gi.t D(wtg)

iments

\JeR<*V
Figure 3

)

Increase in wet weight of total diaphragm with
increasing weight of rat

.
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B.

Control Experiments

A large number of preliminary experiments was conducted
initially in order to test the reliability of the results with
the rat diaphragm assay.

A final group of ten animals is

presented as an internal control for the techniques used,
although these results do not enter into the statistical
analysis of subsequent experiments.

Animals were sacrificed

on three days with conditions as constant as possible.
the four quarter-diaphragms from each animal,

Of

2 were incubated

in glucose without insulin and 2 in glucose plus insulin
The results are described in Fig. 4,

(glucose Up+alfe (mg/g/hr)

(100 uU/ml).

Figure 4. Control. Mean glucose uptake ±S.E.M. In basal
and Insulin-treated quarter&laphragms.

18.

The analysis of variance

(Appendix A) showed that

treatment with insulin had a highly significant effect
(p <.001) by omnibus F-test.

The four groups were then

compared by calculating q (See Table 1).
groups

Insulin-treated

(III and IV) were significantly different (p<.01)

from control groups

(I and II).

The differences between

similarly-treated groups were not significant.

TABLE 1
.f

Mean Glucose Uptake (- S.E.M.) by Quarter-diaphragms

Control

(n=10)

Insulin (n=10)

II

I
2.65±0.33

(Control)

III

2.63-0.33

IV

4.33-0.36

4.33-0.38

TABLE 2
Significance of differences between means for Control Experiment

Groups Tested

q-test

Significance (p)

I vs.

Ill

19.99

< .01

I vs.

IV

20.00

< .01

II vs.

III

20.03

< .01

II vs.

IV

20.05

< .01

I vs.

II

0.29

NS

III vs.

IV

0.04

NS
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C.

In vitro 17^-estradiol

In these experiments,
pg/ml,

2 x 10

-3

uM)

its own control.

(500

was tested in vitro using each animal as

A total of 23 rats was used;

diaphragms were treated as
III,

the effect of 17/^-estradiol

insulin + estradiol;

I,
IV,

control;

II,

in 15,

insulin

insulin + estradiol.

quarter-

(100 uU/ml);
In the 8

remaining animals the fourth quarter-diaphragm was used in
other experiments.

The overall results are shown in Figure

Glucose Uptake

jy /hr)

5.

Figure 5

Mean glucose uptake -S.E.M. for basal, insulintreated and insulin + estrogen-treated rat quarterdiaphragms in vitro.

t

,

f iX
•*

t

,
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The statistical analysis was carried out in 2 groups:
the first where n«23 in which the "treatments" are I#
Control;
and 4,

II,

insulin;

and III,

insulin -f estrogen (Tables 3

Appendix 3) shows that treatment overall had a highly

significant (p<.001) effect but that concurrent treatment
with estradiol in vitro did not alter glucose uptake when
compared to insulin alone.

TABLE 3
Mean Glucose Uptake (isEM) by quarter-diaphragms.
Control^
insulin-treated and insulin + estradiol
n=23
Control (I)

Insulin (II)

Insulin + Estradiol (III)

3.74^0.22

5.25^0.27

5.28-0.26

TABLE 4
Significance of the differences between means for in vitro
estradiol
n=23

Groups Tested

q-test

Significance (p)

I vs.

II

15.82

< .05

I vs.

Ill

15.63

< .05

II vs.

Ill

0.27

NS

If the data is analyzed in the 15 animals in which two
quarter-diaphragms were treated with insulin and estradiol
(Appendix C, Tables 5 and 6),

the results are essentially the
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same:

in vitro estradiol had no effect on insulin-mediated

glucose uptake at incubation periods of 1 hour.

TABLE 5
Mean Glucose Uptake (-S.E.M.) by Quarter-diaphragms.
Control,
insulin-treated, and insulin + estradiol (in 2).
n=15

Control (I)

Insulin (II)

Insulin+Estradiol

3.67±0.31

5.21-0.25

5.25-0. 34

(III,IV)

5.08-0.37

TABLE 6
Significance of the: differences between means for in vitro
estradiol
n=15
Groups Tested

q-test

Significance (p)

I vs.

II

13.04

< .01

I vs.

Ill

13.35

< .01

11.92

< .05

I vs. IV
II vs.

Ill

0.31

NS

II vs.

IV

1.11

NS

III vs. IV

1.42

NS

In a small group of animals (n=4), basal glucose uptake
(no insulin added to incubation buffer) was compared between
quarter-diaphragms from the same animal with and without the
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presence of estradiol 2 x 10

_3

uM.

The difference between the

two groups was not significant by t-test (Table 7).

TABLE 7
Mean Glucose Uptake (^S.E.M.) by Quarter-diaphragms in vitro
with and without estradiol
(Basal)

Control

-j-Estradiol

3.59-0.38

3.53-0.29

The effect of the small quantities of ethanol used to
dissolve the 17/3-estradiol were examined (See Appendix D,
Tables i and ii),

and found to have no significant effects

on either basal or insulin-mediated glucose uptake.

Figure

6 shows the results when ethanol was added to insulin.

Figure 6

Mean glucose uptake is.E.M. in basal, insulin-treated
and insulin + ethanol-treated quarter-diaphragms
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D.

Pre-incubation with 17^-estradiol

In this set of experiments, estradiol was added to the
pre-incubation buffer in a concentration of 2 uM.

There was

no added insulin until the diaphragm was transferred after 15
minutes to the usual incubation medium.

The pre-treated

quarter-diaphragm was incubated in the presence of the usual
_3
(2 x 10

uM) amount of estradiol.

in Figure 7 and Tables 8 and 9.

The results are described
There was no significant

effect of pre-incubation with estradiol, representing a total
of 75 minutes in which the tissue was in contact with estro¬
gen in vitro.

Figure 7

(Analysis of Variance, Appendix E.)

Mean glucose uptake -S.E.M. in basal, insulintreated, and estradiol-preincubated followed by
insulin-treatment rat quarter-diaphragms.
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TABLE 8
Mean Glucose Uptake (-S.E.M.) by Quarter-Diaphragms.
incubation with 17^-estradiol
n=9

Control

(I)

3.22^0.26

Pre¬

Insulin (II)

Insulin, estradiol

4.66-0.19

4.60-0.28

(in:

TABLE 9
Significance of the differences between means for Control
insulin (II) and estradiol preinc (III)
Groups Tested

q

Significance (p)

I vs.

Ill

11.25

< .05

II vs.

Ill

0.82

i

i

11.74

in
o
•

I vs. II

V

2.

(i)

NS

In vivo pretreatment of rats with 17/^-estradiol followed
by incubation of hemidiaphragms with and without insulin
A.

Variation of total weight of the diaphragm

Figure 8 shows the results of two weeks' pretreatment of
two groups of rats. Group I with sesame oil. Group II with
17/3-estradiol (10 ug/100 Gm body weight) injected subcutaneous¬
ly.

Group I (n=19) rats weighed 151.9-3.03 Gm (Mean-S.E.M.)

and Group II,
ficed.

152^3.56 Gm at the time the animals were sacri¬

This represents no significant difference.
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Comparison of Figures 8 and 3 reveals that the slopes
of the lines describing the increase in diaphragm weight as
a function of animal weight are similar for animals that did
and did not receive pretreatments by subcutaneous injection.
In general, however,

the total diaphragm weights are greater

in the pretreated group because these muscles were prepared
as hemidiaphragms and hence required less trimming.

Figure 8. Total weight of diaphragm vs. weight of rats
injected with sesame oil with and without estradiol for
two weeks.

B.

Fasting plasma glucose and IRI concentrations

Since the hemidiaphragms used in these experiments came
from animals which had received sesame oil with and without
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estrogen,

an analysis had to be carried out comparing the

two groups,

two "pretreatments"

(with and without estrogen),

and two "treatments" in vitro (with and without insulin).
In order to determine more precisely the effects of
estrogen pretreatraent,

two subgroups were used to determine

fasting glucose and insulin levels.

Table 10 shows that

there were no differences in final weights of the animals,
plasma glucose or immunoreactive insulin concentrations
after 2 weeks pretreatment and 24-hour fast.

TABLE 10
Mean (-S.E.M.) Fasting Plasma Glucose (mg%), IRI (uU/ml) and
Weight (Gm) in Rats with and without Estrogen Pretreatment
(n=10)
Weight (Gm)

Glucose (mg%)

IRI(uU/ml)

Pretreatment with
sesame oil alone

155-8.3

99.2-3.7

34.0^2.8

Pretreatment with
estradiol

158^5.2

97.6i3.9

33.3±2.9

Significance

NS

NS

NS

(p)*

*By student*s t-test.

C.

Analysis of Data on Glucose Uptake

In Figure 9 glucose uptake per hemidiaphragm is plotted
as a function of the weight of the animal.

There is a con¬

sistent tendency for the muscle of smaller animals to take up
more glucose per gram wet weight than that of larger animals

.
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in both basal and insulin-stimulated states.
observations made by Liebecq (113).

This confirms

While his data show a

non-linear relation at the lower weight range, none of the
animals used in the present study were lighter than 120
grams; the regression lines are significant only for the
estrogen pretreated animals and are shown only to indicate
the general trend.

Figure 9« Relationship of glucose uptake to weight of
rat in estrogen-treated (basal0 , 4-insulin* ) and nonestrogen-treated (basalO, 4-insulin#) rats.
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Table 11 shows the compiled data for glucose uptake in
the basal and insulin-mediated states following in vivo pre¬
treatment of Group I rats with vehicle alone and Group II
with estradiol.
TABLE 11
Mean Glucose Uptake (-S.E.M.) in Hemidiaphragms,
Pretreatment with Estradiol

Effect of

Pretreatment in vivo

Basal

(no insulin)

Insulin (100 uU/ml)

N

Vehicle alone

Estradiol

19

3.49-0.06

2.91-0006

19

4.82-0.06

5.88-0.06

The analysis of variance (Appendix F)
treatment significantly (p®Q.0Q5)
an omnibus F-test.

Similarly,

indicated that pre¬

affected glucose uptake by

insulin treatment and the

interaction of pre-treatment and treatment showed highly sig¬
nificant effects

(p< 0.001).

Figure 10 and Table 12 show the effect of estradiol pre¬
treatment on the insulin uptake of heraidiaphragms in the
basal state and in the presence of insulin.

There are sig¬

nificant differences in both conditions (p^.QOl), estradiol
causing a 16% decrease in basal uptake and a 22% increase in
insulin-stimulated uptake

(Glucose

(Xp+a-ke

(m 9/9/kr)
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<£J.O01

p>

Figure 10. Mean glucose uptake (±S.E.M.) in basal and
insulin-stimulated rat hemidiaphragms showing the effects
of estrogen pretreatment.
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TABLE 12
Significance of the differences between means for glucose uptake
of hemidiaphragms from pre- and non-pre¬
treated rats (estradiol for 2 weeks)
BASAL

Group I
Group II

Mean

SD

N

Variance

(no estrogen)

3.49

0.27

19

0.074

(+ estrogen)

2.91

0.24

19

0.059

SE

df

t-test

P

0.086

36

6.708

<.001

Difference

0.575

INSULIN-STIMULATED
Mean

SD

N

Variance

Group I

4.82

0.26

19

0.066

Group II

5.88

0.26

19

0.069

SE

df

t-test

P

0.087

36

12.309

<.001

Difference

1.065

In Figure 11,

the relative effects

are plotted with

estrogen pretreatment as the independent: variable .

Of note

is that the effects of estrogen in vivo on muscle uptake of
glucose in vitro are not parallel in basal and insulin-stimulated
states;

specifically,

there is a 16% decrease in basal and a

22% increase in insulin-stimulated glucose uptakes with estro¬
gen pre-treatment as compared to control.

The relatively
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larger increment in the latter condition cannot be accounted
for by the change in basal uptake,
direction.

In fact,

which is in the opposite

when examined in this fashion we can

designate the change in glucose uptake

as

"insulin effect".

untreated animals is
it is

103%.

Thus,

(as % of basal uptake)

the insulin stimulatory effect in

38% whereas in estrogen-treated animals

This represents a greater than two-fold increase

in insulin sensitivity.

■5

f

%
J

Animals
x 2.
Wee.Us toitfa sesame, oil

Animals pnrtveafadl X2 u«cKs
uxt^i <7(1-tMmauiioI in sesame <■>« I -

Figure 11. Relative effects of estradiol pretreatment on
mean glucose uptake (±S.D.) for basal and insulin-stimul¬
ated hemidiaphragms. The effeot of estradiol was signi¬
ficant on both basal and insulin-mediated gluoose uptake.
See text.
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Summary of the Results

1)

Using the rat diaphragm in vitro assay for the action
of insulin on glucose, uptake by muscle is sensitive at
physiologic levels of insulin and the differences in
glucose uptake between insulin-treated and untreated
muscle are significant.

2)

There is no significant effect of high pharmacologic
concentrations of 17/^-estradiol on either basal or
insulin-stimulated glucose uptake for incubation periods
up to 75 minutes when added in vitro.

3)

Pretreatment of rats with estradiol for 2 weeks resulted
in no significant changes in weight gain as compared to
controls.

4)

Estradiol pretreatment did not alter fasting plasma
glucose or insulin concentrations.

5)

Estradiol pretreatment caused a significant decrease
in glucose uptake in the basal state as compared to
controls.

(16%)

6)

Estradiol pretreatraent caused a significant increase
in glucose uptake in the insulin-stimulated state as
compared to controls.

(22%)

7)

The effect of estrogen pretreatment on insulin-stimulated
glucose uptake could not be explained by its effects on
basal uptake.
There is thus a greater than two-fold
increase in insulin responsiveness of the muscle from
estrogen-treated animals.

Discussion
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I.

Animal Studies
Following the discovery that anterior pituitary extract

was diabetogenic in the rat and that hypophysectomy ameliorated
the diabetes

(83),

interest arose in the relationship of sex

hormones to diabetes.

Thus,

the experimental-diabetic animal

was the earliest model for the study of the influence of
estrogen on carbohydrate metabolism.
Barnes et al.

(6)

found that the administration of crude

estrogenic preparation

(amniotin)

pancreatectomized dogs.

decreased glycosuria in

Similarly,

Nelson and Overholser

(218),

in a small group of totally pancreatectomized Rhesus monkeys,
found estrone treatment improved survival

of the animals and

that increasing the dose of estrone decreased the glycosuria.
Contradictory evidence was presented by Dolin et al.

(42)

who failed to demonstrate improvement in experimental diabetes
in ferrets;

in fact,

in 90%-pancreatectomized female ferrets

receiving estradiol benzoate,
increased.

Young

(216),

glycosuria and acetonuria

using doses of estrogen higher than

those reported by Barnes and Nelson,
that diethylstilbestrol

(DES)

was surprised to find

had no effect on diabetes while

estriol and estrone exacerbated diabetes mellitus in dogs
made diabetic by injection of anterior pituitary extract.
the same time,

Ingle

(86)

At

demonstrated that DES administered

to partially pancreatectomized non- or mildly glycosuric
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rats resulted in severe glycosuria and hyperglycemia.
obtained similar though somewhat
estradiol.

In normal rats

induced a mild,

less striking results with

on a high carbohydrate diet,

temporary glycosuria.

he went on to show

(87,88)

He

DBS

Using the same system,

that treatment with DBS in intact

animals required larger doses of estrogen to produce this
transient glycosuria

(weeks)

than in diabetic animals

in

which the effect persisted for the length of the experiments
(months).

Similar results were obtained by James et al.

These studies were certainly suggestive of some effects

(90).
of

estrogen on carbohydrate metabolism in diabetic and normal
animals,

but the differing animal models,

tions and doses,

estrogen prepara¬

extent of pancreatic ablation,

duration of

treatment and criteria for study make evaluation of the evi¬
dence difficult.
The South American group of Iloussay,

Foglia,

Rodriguez

and their coworkers performed similar experiments with the
advantages of uniformity of techniques and adequacy of con¬
trols .
Two sets of experiments were performed by Foglia et al.
(54,59)

on the incidence of diabetes

following subtotal

pancreatectomy in male and female rats.

Males did quite

poorly with 100% developing diabetes in six months
blood sugars

150 mg% and fasting glycosuria),

of females became diabetic.

(95%)

(fasting

while only 20%

When the animals were paired-fed
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(i.e.,

male fed only as much as female),

the percentage

diabetic at 2 months was 100 for males and 60 for females.
In forced-feeding experiments conducted for 40 days,

60% of

males and 15% of females became diabetic.
The effect of the gonads was studied by castration
followed by pancreatectomy.
at birth,

80% of animals,

When castration was performed

both male and female,

betic 6 months after subtotal pancreatectomy.
pancreatectomy preceded castration,
of castrated males,

diabetic.

If,

however,

100% of intact males,

40% of castrated females,

tact females developed diabetes in six months.
to go to one year,

became dia¬

80%

and 20% of in¬
When allowed

only 50% of gonadally intact females became

This evidence was

interpreted as showing a

"pro¬

tective " effect of the ovaries on the development of experi¬
mental diabetes

in the rat.

The problem was further studied by Foglia

(59) who showed

that exogenously-administered sex steroids affected the
incidence of diabetes in 95%-pancreatectomized rats.
are summarized in Table

I below.

The data

The statistical significance

TADLE I
Incidence of diabetes in rats castrated at 80-100 Gm body weight
and 95% pancreatectomized one week later, injected daily for six
months with subcutaneous doses, on ad libitum normal carbohydrate
content diet (from Houssay et al. (84)1.
Percent Diabetic © 6 mo
Dose

Control
Estrone
Estrone
Estradiol
DES
DES
Ethinylestradiol

15
50
15
15
50
50

(ug)

Female

46
30
0
12
30
12
25

{n=116)

Male

(n=43)

89

66
50

36

of these data is uncertain although the numbers of animals
are sufficiently largo to suggest that these differences are
meaningful.

Similar data was

obtained in intact and castrated

female rats using estradiol benzoate

(see Table II).

This

evidence points to a protective effect on the development of
diabetes of naturally-occurring and synthetic estrogens in
pharmacoligic doses.
TABLE II
Effect of estradiol benzoate injected daily for six months
on the incidence of diabetes {%) in intact and castrated male
and female rats after 95% pancreatectomy (from Lewis et al. (112))
Female

Male

Intact
Dose

Castrate

Castrate

Intact

(ug)
Cont

Rx

Cont

Rx

Cont

Rx

Cont

Rx

2

43

8

22

16

92

36

61

36

4

21

0

37

8

88

50

87

44

15

71

33

86

12

100

16

100

66

The time course of the appearance of diabetes is
tant,

Lewis et al.

(112)

impor-

found that after 95% pancreatectomy,

diabetes develops in three stages:
1.

"pre-diabetes" -- one to two months of normal
growth, normoglycemia and no glycosuria

2.

"incipient diabetes" — normoglycemia and no
fasting glycosuria but post-prandial glycosuria

3.

"manifest diabetes" — fasting hyperglycemia,
glycosuria and death when not treated

-
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This type of experimentally-induced carbohydrate in¬
tolerance Houssay

(84)

calls

trast to alloxan diabetes.

"pancreatic diabetes"

in con¬

Both are worsened by increased

food intake and are affected by thyroidectomy and corticos¬
teroids.

However,

the acutely-induced diabetes with alloxan,

pituitary extract or total pancreatectomy is different in that
the animals must be maintained on exogenous insulin from the
immediate post-treatment period.

In these animals estradiol

benzoate causes a transient exacerbation of the diabetes but
the animals do not benefit from long-term estrogen thereapy.
As we have seen,

this is in contrast to the subtotally-pan-

createctomized animal which after transient exacerbation,
improves with long-term estrogen
already overtly diabetic,
effect on the course

(146).

If the animal was

adrenalectomy did not have an

(84).

This evidence was seen to point toward several possi¬
bilities:

increased availability of insulin,

sensitivity to endogenous insulin,
betogenic"

factor,

increased

inhibition of some

or direct effects of estrogens

utilization or production.

"dia¬

on glucose

Anatommic data compiled by this

group was used to support the first hypothesis with the
reasoning that when pancreatectomy is partial,

chronic estro¬

gen administration leads to increased insulin secretion.

The*

insulin content of the pancreas is similar in male and female
rats and is not changed by castration

(75)

but the volume of

;

•.

rx

,

.
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islet tissue was said to be greater in female rats

(190).

Estrogen treatment increases the insulin concentration of
the rat pancreas with hyperplasia and sometimes hypertrophy
of islet cells

(146).

This is

in contrast to the

lesser

degree of hyperplasia seen in non-estrogen-treated rats

and

is said to be associated with degranulation of beta cells.
The duration of time required for this effect at the dose
used (15 ug/rat/day)
in castrated,
rats,

is

2-3 months.

hypophysectomized,

Foglia

(58)

found that

95%-pancreatectomized female

4 ug estradiol benzoate per day was better than saline

in ameliorating diabetes after 3 months.

Again,

the pan¬

creases of estrogen-treated animals showed an increase in the
number and size of islets.
this histologic finding;

Girod and Czyba

(68)

confirmed

they demonstrated that estrogen

increased the percentage of beta cells in islets in the head
of the pancreas.
More recently,

Basabe et al.

(8)

have measured blood

glucose and plasma insulin concentrations
rats treated with several steroids.
significant

(but small)

however,

These changes were not evident
blood glucose did not show any

significant difference until 6 months
instituted,

The only group showing a

increase after treatment had been

treated with 17/3-estradiol.
until quite late;

in castrated female

after treatment was

while 2 months were required for significant

fasting insulinemia to appear.
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The authors did not interpret the data as indicating a
diabetogenic effect of estrogen treatment.

However,

it is

of note that plasma insulin levels were elevated earlier than
changes in glucose concentration became evident,

and only

when insulin levels were 1.5-2-fold above control did blood
sugars fall significantly.
increases in blood sugar.

At no time were there significant
An alternative hypothesis would

be that blood sugar is not a sensitive enough indicator of
the peripheral action of insulin and that the hyperinsulinemia
was indeed in response to peripheral antagonism to insulinmediated glucose utilization by tissues not sufficient to
raise plasma glucose values.

It is unlikely that the effects

were secondary to obesity or age since matched controls
injected with olive oil alone showed no significant elevations
of plasma insulin.
Costrini and Kalkhoff (30)

incubated slices of rat

pancreas in vitro and measured immunoreactive insulin release
after glucose stimulus.

Estradiol benzoate in vivo increased

the insulin secretion of the tissue significantly.
effect was seen after three weeks'

treatment.

This

In addition,

post-estrogen treatment glucose concentrations in intravenous
glucose tolerance tests (IVGTT) were lowered significantly.
This betacytotrophic effect of estrogen was thus postu¬
lated on largely indirect evidence.

Rodriguez (146) attempted

to demonstrate a direct effect by implanting pellets of
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estradiol in the rat pancreas

in vivo.

He found that islet

size increased focally the nearer the pellet.
There is conflicting evidence on thi3
al.

(74)

treated rats with progesterone,

point.

Hager et

estradiol,

and human

chorionic somatomammotropin and meas red insulin secretion
from their pancreases in vitro.

sterone increased insulin

secretion but no further increment
were treated with both estrogen ai

ogesterone.

alone led to a smaller than norma

ulin secretory response

Estradiol

to glucose stimulation.
Recently,

Bailey and Matty

(4}

f

incubation of pancreatic tissue for 6

md that in vitro
hours with estradiol

does not affect the insulin secretor
does.
The state of granulation of the beta cells may not
reflect the insulin content of
changes in the amount of acinai
in insulin concentration
any change

in the total

One must conclude,

in the

can result in changes
pancx

>a

-ithou,

t'

amount of insulin in the gland

therefore,

ei
(75).

that the evidence is inconclu¬

sive as to whether estrogen promotes insulin secretion by a
direct betacytotropic effect.
The findings by Houssay and Foglia that estrogens have
a protective effect on the development of diabetes and can
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improve the degree of glycosuria in the diabetic animal is
compatible with our results showing an enhancement of glucose
uptake in the insulin-stimulated state in animals pretreated
with estrogen.

Contrary to the previous studies, we have

found that estrogen (specifically 17/^-estradiol) increases
the insulin sensitivity of skeletal muscle and thus do not
need to postulate an increase in endogenous insulin produc¬
tion with estrogen treatment.

It was only in 95%-pancreatec-

tomized animals that Houssay and Foglia demonstrated a bene¬
ficial effect of estrogen.

We propose that the enhanced

response of skeletal muscle to the remaining small endogenous
insulin output of these animals would account for the observed
effects with estrogen treatment.
We found that short-term treatment with estradiol was
not associated with changes in fasting insulin or glucose
concentrations.

We did, however,

find that the diaphragm

muscle of treated animals took up less glucose in the basal
state when compared to control.

One might expect this rela¬

tive deficit (about 20%) in glucose uptake in vitro to be
reflected in the fasting in vivo glucose concentration.
There are two related explanations for this apparent contra¬
diction.

In the post-absorptive state (i.e.,

after a 24-hour

fast as in our animals) the vast bulk of circulating glucose
is taken up by non-insulin-dependent tissues, mainly neural.
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with muscle metabolism relying largely on fatty acids and
ketone bodies

as sources of energy.

Even when glucose,

insulin and fatty acids are present in greater concentrations
(e.g.,

after a meal)

glucose accounts for as

fifth of the oxidative metabolism in muscle.

little as one
Thus,

even a

relatively large change in muscle uptake of glucose in the
fasted state would not affect overall blood glucose

levels

significantly.
The suggestion that insulin action may be enhanced by
other hormones has received little attention.
have studied the effects
(187)

and in women

of estradiol dipropionate in rabbits

(189).

glucose tolerance tests

In their animal studies,

(IVGTT)

ized and intact female rabbits
muscular estrogen

Talaat et al.

intravenous

were performed on ovariectomafter 3

(0.02 mg/kg/day).

and 7 days of intra¬

They found that:

1.

after 7 days* treatment, there were sig¬
nificant decreases in 30 and 60 minute
blood glucose and increased sensitivity
to insulin lasting up to three days after
treatment was discontinued

2.

ovariectomy caused a significant rise in
the glucose tolerance curves 2 and 4 weeks
post-operatively; ovariectomy caused a de¬
crease in sensitivity to exogenous insulin
as measured by % reduction of fasting glu¬
cose.

These data confirm our own observations that the enhanced
response in muscle is seen with insulin treatment.

These

effects in the intact animal were small and no changes were
observed in fasting blood sugars.
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Similar investigations were carried out in normal
volunteers

and insulin-dependent diabetics

Doses of estradiol diproprionate
7 to 12 days)

(women)

(189).

(5 mg every other day for

caused a significant lowering of the fasting

serum glucose concentrations in both arterial
samples of the normal women.

and venous

The effect of a single dose

of 25 mg of estradiol resulted in a significant increase in
glucose utilization at 60 and 90 minutes of the oral glucose
tolerance test.

These effects were not seen in diabetics.

Talaat and his coworkers interpreted these results

as

showing that estrogen stimulation of beta cells improves
glucose tolerance in normal women whereas in diabetics an
absent endogenous insulin production precluded such effects.
They did not perform insulin assays on their subjects and
our studies would suggest a different mechanism to account
for the observed increase in glucose utilization.
difficult to understand two of their findings:

It is

first,

the

decrease in fasting blood sugar with estrogen treatment,
and,

second,

the lack of any observed action in diabetics

who were receiving exogenous insulin.
It would appear,

then,

that carbohydrate tolerance is

affected when estrogenic substances are administered.

There

are earlier data to support our findings that glucose tolerance
may be improved.

However,

the proposed mechanism,

namely that

of stimulation of endogenous insulin secretion by estrogen.
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is neither satisfactory nor clearly established.

The present

study has shown that increased sensitivity to insulin of
skeletal muscle may play a role in the enhanced uptake of
glucose by this tissue.

A brief survey of the action of

these hormones at a cellular level may be appropriate.

No

attempt at a complete review will be made here since the
reader can refer to excellent recent papers by Jensen et al.
(92)

on sex steroids and by Levine (111) and Cuatrecasas

(33)

on insulin.
The action of insulin on glucose metabolism is not com¬
pletely understood but it is clear that at least two functions
can be ascribed to insulin in muscle:
1.

promoting glucose transport into cells,

and

2.

increasing glucose utilization, probably by
increasing the activity of glycogen synthe¬
tase.

In the experiments reported above, we could not differentiate
between these two functions since glycogen formation was not
measured.

It is, therefore, possible that estrogen affected

either or both the above pathways of insulin action.
It is well known that the rate limiting step in the
utilization of glucose by muscle in the absence of insulin
is the rate of transport of the sugar across the cell mem¬
brane whereas in the presence of insulin,

the hexokinse step

in the formation of G-6-P determines the overall rate.

In

our studies, basal glucose uptake was depressed by estrogen
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treatment.

Thus,

it would appear that the muscle cell mem¬

brane becomes relatively less permeable to passive transfer
of glucose by simple diffusion (the concentration of glucose
used iri vitro was not great enough to saturate the process by
mass action).
enhanced.

In contrast,

insulin-stimulated uptake was

It is possible that this represents an increase in

activity in intracellular glucose utilization.

There is some

evidence from studies in rat uterine muscle to suggest such
pathways of increased glucose utilization.

Barker and

Warren (5), using radioactively-labelled glucose,

observed

that 6 hours after the injection of estradiol in vivo the
majority of estrogen stimulation of glucose utilization in
the uterus occurs by increasing hexose monophosphate shunt
activity; specifically,
2-fold by 12 hours.

G6PD and 6PGD activities increase

Other studies have shown that an increase

in uterine glycogen can be detected 1-2 hours after estrogen
administration (92,164).
Effects have also been observed on glucose transport in
this system.

Roskoski and Steiner (148) have shown that

estrogen administration (single dose of 1 ug) increases the
rate of 3-o-methyl-D-glucose transport into uterine cells
in vitro.

This finding is interesting in that it demon¬

strates increased uptake of a non-insulin-dependent sugar
while the present investigation showed that glucose uptake
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in the non-insulin treated diaphragm was depressed by estro¬
gen treatment.

Aside from the obvious discrepancies in the

biological models*,

this may be related to the duration of

estradiol administration.

Their study also showed that estra¬

diol had no effect in vitro,

a finding that complements our

demonstration of the lack of in vitro effect of estradiol on
insulin-dependent glucose uptake.

The action on uterine

muscle appeared after 1 hour indicating that the increase is
not due to a primary physio-chemical interaction of the hor¬
mone with the sugar transport system in the membrane.
This may help us understand the interaction of hormones
whose sites of action are believed to be different -- that is,
while insulin is believed to promote membrane transport of
glucose and stimulate glycogenesis in muscle cells, estradiol
is thought to act on specific nuclear receptors to activate
the transcription of new mRNA with subsequent alterations of
intracellular metabolism.
Our studies failed to demonstrate an effect of in vitro
treatment of diaphragm muscle with estradiol for up to 75
minutes at supranormal concentrations.

Taken by itself,

this

*The tissue specificity of estradiol has been studied with
respect to receptor sites ifhich bind estrogen.
Jensen et
al. (93) have shown that rat diaphragm muscle does not
accumulate the hormone under physiological circumstances as
well as uterine muscle does.
This may represent a quanti¬
tative rather than qualitative difference and, although,
fewer in number, estrogen receptors are present in skeletal
muscle (Dr. A. Eisenfeld, personal communication).

,
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fact does not tell us very much.

There is some evidence that

the effects of estrogen on uterine muscle can be manifested in
as early as 60 minutes (92).

On the other hand,

the skeletal

muscle preparation may be less sensitive than other specific
target organs for estradiol; hence, more prolonged exposure
to estrogen might be needed to detect any effects on glucose
uptake.

Indeed,

for estrogen,

in uterine muscle which has a high affinity

the effects on glycogen synthesis are not seen

until 1 to 2 hours after administration.
however,

We were successful,

in demonstrating significant alterations in the

glucose uptake of the muscle in vitro when estrogen was
administered for two weeks in vivo.
vehicle-treated controls,

When compared to

the estrogen-treated hemi-diaphragms

showed a 16% lower basal glucose uptake and a 22% higher
insulin-stimulated uptake.
The lack of an acute effect in tissues other than uteri
would thus seem to be a quantitative matter.

In our hands,

diaphragm muscle could not be said to "not respond to estro¬
gens"

(164).
We need not hypothesize a direct effect of estrogen on

glycogen formation in diaphragm muscle, howeverf

Our results

can be explained on the basis of the markedly increased insu¬
lin sensitivity of the hemi-diaphragm which we have demonstrated
following estrogen treatment.

In vivo,

this 2 to 3 fold

increase in the sensitivity of muscle to insulin would result
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in synthesis and an increased pool of intracellular glycogen*
When removed from the animal, muscle metabolism becomes de¬
pendent on intracellular energy stores.

Thus,

tissues from

estrogen-treated animals, having a higher glycogen content,
would have a decreased glucose need.

This is especially true

in the basal state in which muscle depends on fatty acid and
ketone utilization for the greater part of its energy require¬
ments with glucose being taken up only for glycogen formation
(45).

A consequent decrease in basal glucose uptake would be

expected,

as we have found.

In the insulin-stimulated experimental state, however,
the opposite holds true.
sensitive to insulin,
muscle.

Estrogen-treated muscle, highly

took up more glucose than untreated

Glycogen synthesis and hexose monophosphate shunt

activity may account for this increased glucose utilization.
We can only speculate'as to how estrogen induces increased
insulin sensitivity.

Binding sites have been demonstrated

to exist in cell membranes for both insulin (33)
(93).

and estrogen

Numbers of insulin receptors or their affinity may be

altered by estrogen.

Both steroid (182)

and peptide (200,203)

hormones have effects on intracellular 3',

5'-cyclic AMP,

certainly a likely candidate as a point of interaction.
addition,
C

14

In

S^vik (165) has demonstrated that puromycin inhibits

-glucose incorporation into glycogen but has no effect
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on glucose uptake.

Thus,

there may be a protein synthesis

dependent (enzyme synthetic) step in the insulin-mediated
formation of glycogen.

Similarly,

in isolated rat uterine

muscle puromycin blocks the estrogen stimulation of glucose
metabolism,

including glycogen formation (92).

There would

thus appear to be several possible sites for this interaction
to occur
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II.

Studies of women taking oral contraceptives
Numerous reviews of this subject are available,

example,

Elgee (44),

most recently.

Spellacy (167),

Beck (12).

for

Yen and Vela (215)

and

The reader is referred to these

sources for a more comprehensive discussion.
The earliest reports on impaired carbohydrate metabolism
in women on oral contraceptive agents observed that blood
sugars were elevated in fasting subjects and that some overtly
diabetic glucose tolerance tests developed.
nal report (202),

In Waine's origi¬

4 of 8 patients placed on Enovid (mestranol

and norethynodrel) developed diabetic glucose tolerance tests.
Similar experience was reported by others

(24,

136,

174) with

this agent and other combinations of these steroids for
treatment periods ranging from 1 month to more than 8 years.
Wynn and Doar (212) reported a large series of women taking
various agents and found up to 3/4 of healthy women with
abnormalities in their OGTT and 13% developing chemical
diabetes.

Variations in the agents used and in the prior

metabolic status of the subjects made it impossible to draw
any conclusions from these early studies.
Deterioration of glucose tolerance in normal subjects
taking estrogen alone has been reported.

Goldman and

Ovadia (71) found that IVGTT worsened significantly in post¬
menopausal and post-partum women receiving DES or conjugated
estrogens (as Premarin) by ten days of therapy.

Subjects

.
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who were prediabetic by history showed more marked effects.
Pyorala et al.

(141),

in a prospective study comparing the

effects of mestranol + norethisterone acetate and ethinyl
estradiol + norethisterone acetate,

found increases in the

numbers of subjects with abnormal OGTT after 20 days'
ment that were larger for the first group.
treated with sequential agents,

treat¬

When women were

the glucose disappearance (k)

values of the IVGT tests decreased significantly during ethinyl
estradiol treatment with no change when megestrol acetate (a
progestogen) was added.

They concluded that the estrogenic

component of the oral contraceptives was responsible for the
carbohydrate intolerance but that there were differences
between various estrogens in the degree of impairment
caused.
Dipaola et al.

(40,41) compared mestranol with ethinyl

estradiol and concluded that 50 ug per day of the latter had
no effect on prednisone glucose tolerance tests but that
mestranol at doses of 40-80 ug per day elevates glucose con¬
centrations during the test.

However,

their subjects were

taking other agents concurrently (especially progestogens).
Javier et al.

(91) investigated the effects of mestranol

(75 ug per day) in premenopausal women.

They found that the

deterioration in OGTT and cortisone glucose tolerance tests
were not associated with increased plasma insulin levels
after a glucose load nor with fasting hyperglycemia.
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Beck (10) used estradio}.,

estriol and ethinyl estradiol

daily for two weeks in Rhesus monkeys tested before and during
treatment with IV glucose tolerance tests.

He found no signi¬

ficant changes in the serum glucose disappearance rate or
plasma insulin concentrations.

However,

exogenously-admini¬

stered insulin resulted in a more gradual development of hypo¬
glycemia indicative of a decreased sensitivity of the animals
treated with estrogen.

In contrast, mestranol produced a

significant increase in plasma insulin response to glucose
and a decreased sensitivity to exogenous insulin; glucose
disappearance, however, was unchanged.
In patients taking combination or sequential estrogenprogestogen agents the results are even more conflicting.
In Gershberg et al.'s

(65) study of 59 women on a com¬

bination of 5 mg norethynodrel and 75 ug mestranol,

10% had

elevated fasting blood glucose concentrations as compared to
the normal mean.

In addition,

1 and 2-hour glucose concen¬

trations were raised after an oral glucose load in 20 and 50%
of subjects,

respectively.

Posner et al.

(139,140) have shown the same combination

to significantly impair IVGTT over a 2-3 month period when
compared to pretreatment control values.
treatment,

With continued

these effects persisted for 18 months in those

subjects who gave a history suspicious for diabetes but
normal subjects tended to return to their pretreatment levels
after this period of time.
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Spellacy et al.

(175),

in a study conducted for 1 year,

observed that the same combination (Enovid)

increased the

total serum glucose during IVGTT, but the largest changes
were seen in subjects who were older,

obese or prediabetic.

Plasma insulin values showed significant elevations at 15
minutes,

30 minutes,

1 and 2 hours after a glucose load but

fasting insulin levels were unchanged.
that the oral glucose tolerance test,

Of note is the fact
especially when preceded

by glucocorticoid priming, was more frequently reported as
abnormal in all these studies than the intravenous test (167).*

*While not directly pertinent to the question of estrogen and
carbohydrate tolerance, it would be useful to mention the
studies using progestational agents since much of the work
on birth control pills has been done with combination agents.
Muggia et al. (125) and Benjamin and Casper (16) were the
first to report impaired carbohydrate tolerance with medroxy¬
progesterone and 17 -hydroxyprogesterone treatment.
The use
of the former agent by Gershberg et al. (66) decreased glucose
tolerance in potential diabetics and diabetics.
Chlormadinone (Vermeulen et al. (199) and Beck (11)), ethynodiol diacetate (Goldman and Eckerling(69) and megestrol acetate
(Spellacy et al. (178)) did not significantly affect glucose
tolerance in normal women but did impair glucose disappearance
rates during IVGTT in diabetics.
Beck (10) tested several progestogens in Rhesus monkeys and
found that some of the synthetic agents (e.g., chlormadinone
acetate) increased the sensitivity of the pancreatic islet
cell to a hyperglycemic stimulus.
The overall effects of the progestogens on carbohydrate
tolerance seem to be secondary to the combined estrogen.

j
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Certainly,

most of the changes in carbohydrate tolerance seen

with estrogens

are small in normal women

seems to be related to age,
diabetes

parity,

(12).

Deterioration

pre-existing or subclinical

and a family history of diabetes.

This fact may only

be due to the insensitivity of the usual investigatory methods
(i.e.,

glucose tolerance tests)

but does represent what seems

to be a widespread clinical observation.
Thus,

there is some evidence that combinations of 19-

nortestosterone derivative progestins and mestranol impair
carbohydrate tolerance in response to a glucose load
few studies report fasting hyperinsulinemia,

(12).

A

but the most

frequent picture is mild elevation of glucose and insulin
concentrations during the glucose tolerance tests after long¬
term treatment with oral contraceptive combinations.

Our

studies show that short-term estradiol treatment increases
the sensitivity of skeletal muscle to insulin while decreasing
glucose utilization in the basal state.

This discrepancy may

be due to the previously mentioned difficulty of detecting
effects on muscle metabolism as part of the overall state of
carbohydrate tolerance in the intact subject.

The effects

of the sex steroids on a host of systems

make it

probable that a number of aspects
be affected,
effects.

(107)

of insulin metabolism could

in addition to well-established

Furthermore,

(46,81)

the chronic nature of the treatment

with oral contraceptives raises a new problem,
growth hormone.

hepatic

that of

.
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This subject is quite extensive and only brief mention
will be made here.

Houssay and Biasotti had shown in 1931

that hypophysectomy improved the diabetes of pancreatectomized
animals.

In 1947,

these findings
phragms

Krahl and Cori

(103,104,131)

reproduced

and also showed that while the isolated dia¬

of diabetic rats take up less glucose than normal,

hypophysectomy returns
Recently,
in vivo,

the uptake to normal.

Hjalmarson

(82)

showed that growth hormone

and in vitro when combined with dexamethasone,

(GH)

caused

a decreased sensitivity to insulin in diaphragm muscle.
Daughaday and Kipnis

(36)

have reviewed the subject of

insulin antagonism by growth hormone.

The effect of GH is

on

glucose uptake by tissues and not on insulin secretion per se.
In fact,

there is some evidence to suggest that GH elevates

pancreatic insulin content and islet cell volume

(1),

and

that it may increase the sensitivity of beta cells to glucose
stimulation

(20).

Frantz and Rabkin
gen elevates

(61)

were the first to show that estro¬

the HGH concentrations

pregnant rats,

in men and women.

GH is elevated above the

pregnant female rats

In

levels seen in non¬

(159).

There have been several reports of increased fasting GH
levels
(214)

in women on oral contraceptive agents.

Yen and Vela

found that ethinyl estradiol and mestranol elevated

ambulatory fasting HGH levels at the same time as increasing
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plasma insulin concentrations.

Spellacy has

elevations with Enovid after 3 months
In addition,

(176)

found similar
and one year

(170).

an enhanced GI-I response to insulin-induced hypo¬

glycemia was found.

In contrast.

Yen and Vela

that GH values return to normal baseline after

(215)

found

3 months of

treatment and thus may not play a role in the altered carbo¬
hydrate metabolism seen with chronic contraceptive steroid
use.
Davidson and Holzman

(37)

observed that normal

females

on a combination of 50 ug mestranol and 1 mg norethindrone
showed an impairment in the fall in glucose and an enhancement
of GH response following tolbutamide.

This was interpreted as

secondary to the insulin antagonism induced by GH.
There is

a midcycle augmentation in GH response to

arginine infusion coincident with the preovulatory burst in
plasma estrogen in normal women.

Clomiphere citrate blunts

this

(40).

arginine-induced GH response
Thus,

at least some of the impairment in carbohydrate

tolerance seen with synthetic estrogen administration may be
a consequence of the elevations in GH.

The long-term effects

of GH on insulin sensitivity of tissues is not well esta¬
blished
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Conclusions

Our studies demonstrate that estradiol
sensitivity of diaphragm muscle to the

increases the

action of insulin,

probably by increasing glucose utilization.

This supports

the findings that estrogens have a protective effect on the
development of diabetes

following subtotal pancreatectomy.

We did not show any increase in endogenous
to account for increased glucose uptake;

insulin secretion

improved tolerance

to carbohydrate is secondary to augmented uptake by peripheral
tissues more sensitive to circulating insulin.
literature on oral contraceptives

indicates

progestin combinations may be diabetogenic.
thetic steroids

Reviev; of the

that estrogen/
However,

are implicated most frequently,

syn¬

and mestranol

combined with a 19-nortestosterone-derived progestin seems to
impair glucose tolerance by inducing insulin resistance.

It

is possible that prolonged treatment with these agents ele¬
vates concentrations of growth hormone which antagonizes
insulin action.
Our failure to show an effect on glucose uptake with

in vitro administration of estradiol may have been related to
the relative insensitivity of skeletal muscle to estrogen.
However,

our demonstration of highly significant effect with

in vivo administration suggests that estrogen acts in some
fashion to increase insulin sensitivity of muscle 2 to 3
times above control.

The decrease in basal glucose uptake
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combined with an increase in insulin-mediated uptake suggests
that either directly,

or via increased insulin sensitivity,

intra-cellular glycogen content is elevated during in vivo
estrogen treatment.
We can only speculate as to the site of interaction of
these hormones but further studies are needed to clarify this
problem.

Appendices

SS = sum of squares
df = degrees of freedom (n-1)
MS a mean square
* = repeated measures factor used to test the effects of
treatment
Treatment = Variance between groups

(control,

-i-insulin,

etc.)

Treatment by animal = Interaction
Animals = variance within groups

The S.E.M. calculated for q-test using the following equation

where (MSis the mean square of the interaction

Appendix A

Analysis

of Variance Table for Glucose Uptake

(Control

Expt.)

Source

SS

df

MS

F-test

Treatment

28.497

3

9.499

135.644

27

0.070

9

4.676

*Treatment by
animal
Animals

1.891
42.087

P

<.001

Appendix 13

Analysis of Variance Table for Glucose Uptake

(In vitro estradiol)

Comparison of three groups; Control,
insulin, insulin-festradiol

Source

SS

df

MS

F-test

Treatment

35.474

2

17.737

83.193

*Treatment by
animal
Animals

9.381

44

0.213

84.638

22

3.847

P

< .001

Appendix C

Analysis of Variance Table for Glucose Uptake

(Iri vitro estradiol)

Comparison of four groups; Control,
insulin, insulin-i-estradiol ( 2 )

*

N=15

Source

ss

df

MS

F-test

Treatment

25.819

3

8.606

40.996

8.817

42

0.210

91.334

14

6.524

*Treatments by
animal
Animals

P
< .001

Appendix D

Analysis of Variance Table for Glucose Uptake (Ethanol)
parison of three groups:
control, insulin and
insulin plus ethanol.
n«=10

MS

F-test

P

2

8.412

52.285

<.001

2.896

18

0.161

32.528

9

3.584

Source

SS

Treatment

16.823

*Treatments by
animal
Animals

df

Com

Table i
Mean Glucose Uptake (-S.E.M.) by Quarterdiaphragms,
insulin, and insulin+ethanol

Control

(I)

4.16-0.31

Insulin

(II)

5.79-0.36

Control,

Insulin-i-ethanol

(III)

5.69-0.40

Table ii
Significance of differences between the means for Ethanol
Groups tested

q

Significance

I vs.

II

12.90

< .05

I vs.

Ill

12.09

<.05

II vs.

Ill

0.82

NS

(p)

Appendix E

Analysis

of Variance Table for Glucose Uptake

(Preincubation)

n=9

Source_S3_df_MS_F-test_p
Treatment
*Treatment by
animals
Animals

12.039

2

6.020

2.161

16

0.135

10.944

8

1.368

44.572

<.001

Appendix F

Analysis of Variance Table for Glucose Uptake (Pretreatment
with and without estradiol, treatment with and without insu¬
lin in two Groups of 19 rats).
Repeated Measures Design.

Source

SS

df

MS

87.527

4857.3

<

.001

1

12.776

708.9

<

.001

0.649

36

0.018

106.518

75

1.420

1.143

4.424

36

0.123

Treatment

87.527

1

Pretreatment by
treatment

12.776

♦Treatment by
animal
TOTAL

.... .

=0.005

1

*Animals

.P

9.300

1.143

Pretreatment

F-test
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